658084-23-2 | SU11274

Chemical type

• Selective c-Met inhibitor

^[1]

• Small molecule inhibitor of c-Met (hepatocyte growth factor receptor)
• ATP-competitive tyrosine kinase inhibitor

^[2]

Key properties

• Inhibits c-Met phosphorylation
• Reduces viability and migration in cancer cells

^[1]

• Inhibits HGF-dependent signaling and phosphorylation of c-Met
• Induces autophagy via increased LC3-I to LC3-II conversion and Beclin-1 upregulation
• Causes time- and dose-dependent cell growth inhibition, G1 cell cycle arrest, and autophagic cell death
• Activates ERK and p53 pathways, leading to Bcl-2 phosphorylation
• Effective at low nanomolar concentrations (e.g., 100 nM for autophagy induction in A549 cells)

^[2]

• Suppresses growth of colorectal carcinoma, lung, breast, and liver cancer models
• Used in preclinical studies

^[1]

• Therapeutic agent for non-small-cell lung cancer (NSCLC) treatment
• Inhibitor of aberrant c-Met expression in cancers
• Research tool to study autophagy and apoptosis in tumor cells

^[2]

Classification by use

• Chemicals used in targeted cancer therapy
• Tyrosine kinase inhibitors

^[1]

• Chemicals used as kinase inhibitors
• Chemicals used in cancer therapy and autophagy induction

^[2]

A trustworthy factory and manufacturer

Demei Chemical Technology Co., Ltd. is a modern high-tech enterprise integrating R&D, production, and sales. The company's founder, Dr. Arron, born in April 1975, graduated from the School of Mechanical Engineering at Yanshan University and has been engaged in research in the fields of mechanical engineering and chemical synthesis for many years. The company's products focus on the chemical industry, primarily dealing in chemical raw materials and chemical production machinery and equipment. With its strong technical capabilities, advanced production equipment, and strict quality management system, the company has earned the trust of customers worldwide.

1. [Cite:1] PHA-665752’s Antigrowth and Proapoptotic Effects on HSC-3 Human Oral Cancer Cells, Int. J. Mol. Sci., 2024, 25(5), 2871
2. [Cite:2] Activation of ERK–p53 and ERK-Mediated Phosphorylation of Bcl-2 Are Involved in Autophagic Cell Death Induced by the c-Met Inhibitor SU11274 in Human Lung Cancer A549 Cells, Journal of Pharmacological Sciences, Volume 118, Issue 4, 2012, Pages 423-432